The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate development, innovation and establishment of adoptive cellular therapy clinical trials for treatment of pediatric patients (18 years or younger) with solid tumors. Specifically, UG3 phase of the awards will support preclinical, translational and IND-enabling studies that lay groundwork for UH3 early stage clinical trials testing adoptive immune cell therapies in pediatric patients with solid tumors. This FOA is published in parallel with RFA-CA-22-028 and RFA-CA-22-030 with an aim to develop treatments for adult patients with solid tumors and to establish a coordinating center respectively. The awards funded through these three FOAs will collectively comprise the Cancer Adoptive Cellular Therapy (Can-ACT) Network.
Letter of Intent Due Date(s): 30 days prior to application due date
Application Due Date: October 28, 2022; June 30, 2023
RFA-CA-22-029 Expiration Date July 01, 2023
Application budgets may not exceed $900,000/year in direct costs for UG3 phase and $1,500,000/year in direct costs for UH3 phase (excluding sub-award F&A costs) and must reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is two years for UG3 phase and three years for UH3 phase.